Zevra Therapeutics, Inc.
ZVRA Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$9.53
KIRA · Stoqly’s AI analyst, in plain words
- Zevra Therapeutics, Inc. had $106M of revenue in fiscal 2025, up 350.9% on the year before. Over five years, revenue changed +51.6% a year on average.
- Its operating margin was −59.1%, up 309.4 pts: of every 100 in sales, about −59 is left after running the business.
- Zevra Therapeutics, Inc. made $83.2M of net profit in fiscal 2025.
- Free cash flow was −$2.4M in fiscal 2025, −2.3% of revenue.
- Zevra Therapeutics, Inc. has $129M more cash than debt.
Market cap
$585M
P/E
10.1x
Revenue
$106M
Net income
$83.2M
Free cash flow
−$2.4M
Operating margin
−59.1%
Zevra Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+350.9%
Yes. Sales grew 350.9% last year.
Does it make a profit?
78.2%
Yes. It keeps 78.2% of every sale as profit.
Does profit turn into cash?
−2.3%
No. It spent more cash than it brought in.
How healthy are the accounts?
5 / 8
Mixed. It passes 5 of 8 health tests.
How is the share priced?
10.1x
One share costs 10.1 times its yearly profit per share.
What Zevra Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 9, 2026
- Legal name
- ZEVRA THERAPEUTICS, INC.
- CIK
- 0001434647
Zevra Therapeutics, Inc. · ZVRA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $28.7M | $10.2M | $27.5M | $23.6M | $106M |
| Revenue growth | 115.6% | −64.5% | 170.3% | −14.0% | 350.9% |
| Gross margin | 92.8% | 97.8% | 89.3% | — | — |
| Operating margin | 27.0% | −418.9% | −180.6% | −368.5% | −59.1% |
| Net income | −$8.6M | −$26.8M | −$46.0M | −$106M | $83.2M |
| Net margin | −29.9% | −263.5% | −167.7% | −446.9% | 78.2% |
| Diluted EPS | −$2.11 | — | — | −$2.28 | $1.35 |
| Cash | |||||
| Cash from operations | $10.4M | −$18.7M | −$33.5M | −$69.7M | −$1.6M |
| Capital expenditure | $0.1M | $0.1M | $0.3M | $0.0M | $0.8M |
| Free cash flow | $10.3M | −$18.8M | −$33.8M | −$69.7M | −$2.4M |
| FCF margin | 36.1% | −185.1% | −123.2% | −295.0% | −2.3% |
| Share buybacks | $2.8M | $4.7M | $3.4M | $0.0M | — |
| Share count change | 647.7% | — | — | — | 23.8% |
| Debt and strength | |||||
| Cash and short-term investments | $112M | $82.4M | $67.7M | $69.5M | $191M |
| Debt incl. finance leases | — | — | $5.1M | $59.5M | $61.9M |
| Shareholders' equity | $102M | $75.1M | $61.9M | $39.7M | $155M |
| Current ratio | 27.2x | 7.7x | 1.2x | 2.5x | 5.7x |
| Interest coverage | 34.2x | −127.1x | −33.0x | −11.8x | −7.9x |
| Returns and quality | |||||
| Return on capital | — | — | — | −231.6% | −236.3% |
| Return on equity | −48.5% | −30.3% | −67.2% | −207.8% | 85.7% |
| Return on tangible equity | −61.9% | −35.6% | — | — | 54.1% |
| Piotroski F-score | 4 | 2 | 2 | 2 | 5 |
| Altman Z'' | 17.6 | −5.9 | −8.4 | −10.3 | −0.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$2.5M
6 insiders
Of sales under plans
95%
$2.4M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Zevra Therapeutics, Inc. · ZVRA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $9.53 a share, the company is worth $585M: 10.1 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001434647). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.